Center-Authored Papers

Filters: Author is Pro, Barbara  [Clear All Filters]
Journal Article
Hsi ED, Horwitz SM, Carson KR, Pinter-Brown LC, Rosen ST, Pro B, Federico M, Gisselbrecht C, Schwartz M, Bellm LA et al..  2017.  Analysis of Peripheral T-cell Lymphoma Diagnostic Workup in the United States.. Clinical lymphoma, myeloma & leukemia. Abstract
Fanale MA, Horwitz SM, Forero-Torres A, Bartlett NL, Advani RH, Pro B, Chen RW, Davies A, Illidge T, Huebner D et al..  2014.  Brentuximab vedotin in the front-line treatment of patients with CD30+ peripheral T-cell lymphomas: results of a phase I study.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 32(28):3137-43. Abstract
Hoppe RT, Advani RH, Ai WZ, Ambinder RF, Aoun P, Bello CM, Bierman PJ, Blum KA, Chen R, Dabaja B et al..  2012.  Hodgkin Lymphoma, Version 2.2012 Featured Updates to the NCCN Guidelines.. Journal of the National Comprehensive Cancer Network : JNCCN. 10(5):589-597. Abstract
Hoppe RT, Advani RH, Ai WZ, Ambinder RF, Bello CM, Bierman PJ, Blum KA, Dabaja B, Duron Y, Forero A et al..  2011.  Hodgkin lymphoma.. Journal of the National Comprehensive Cancer Network : JNCCN. 9(9):1020-58.
Zelenetz AD, Wierda WG, Abramson JS, Advani RH, Andreadis BC, Bartlett N, Bellam N, Byrd JC, Czuczman MS, Fayad LE et al..  2013.  Non-Hodgkin's lymphomas, version 1.2013.. Journal of the National Comprehensive Cancer Network : JNCCN. 11(3):257-72;quiz273. Abstract
Zelenetz AD, Wierda WG, Abramson JS, Advani RH, Andreadis BC, Bartlett N, Bellam N, Byrd JC, Czuczman MS, Fayad L et al..  2012.  Non-Hodgkin's Lymphomas, version 3.2012.. Journal of the National Comprehensive Cancer Network : JNCCN. 10(12):1487-98. Abstract
Zelenetz AD, Abramson JS, Advani RH, Andreadis BC, Bartlett N, Bellam N, Byrd JC, Czuczman MS, Fayad LE, Glenn MJ et al..  2011.  Non-Hodgkin's lymphomas.. Journal of the National Comprehensive Cancer Network : JNCCN. 9(5):484-560.
Advani RH, Ansell SM, Lechowicz MJ, Beaven AW, Loberiza F, Carson KR, Evens AM, Foss F, Horwitz S, Pro B et al..  2016.  A phase II study of cyclophosphamide, etoposide, vincristine and prednisone (CEOP) Alternating with Pralatrexate (P) as front line therapy for patients with peripheral T-cell lymphoma (PTCL): final results from the T- cell consortium trial.. British journal of haematology. 172(4):535-544. Abstract
Horwitz SM, Pinter-Brown LC, Rosen ST, Pro B, Hsi ED, Federico M, Gisselbrecht C, Schwartz M, Bellm LA, Acosta MA et al..  2016.  A prospective cohort study of patients with peripheral T-cell lymphoma in the United States.. Cancer. Abstract
Gopal AK, Pro B, Connors JM, Younes A, Engert A, Shustov AR, Chi X, Larsen EK, Kennedy DA, Sievers EL.  2016.  Response assessment in lymphoma: Concordance between independent central review and local evaluation in a clinical trial setting.. Clinical trials (London, England). 13(5):545-54. Abstract
Coiffier B, Pro B, Prince MH, Foss F, Sokol L, Greenwood M, Caballero D, Morschhauser F, Wilhelm M, Pinter-Brown L et al..  2014.  Romidepsin for the treatment of relapsed/refractory peripheral T-cell lymphoma: pivotal study update demonstrates durable responses.. Journal of hematology & oncology. 7:11. Abstract
Pro B, Horwitz SM, Prince MH, Foss FM, Sokol L, Greenwood M, Caballero D, Morschhauser F, Wilhelm M, Padmanabhan Iyer S et al..  2016.  Romidepsin induces durable responses in patients with relapsed or refractory angioimmunoblastic T-cell lymphoma.. Hematological oncology.